19 analysts have shared their evaluations of Exelixis EXEL during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 5 | 6 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 3 | 3 | 0 | 0 |
| 2M Ago | 2 | 2 | 2 | 0 | 0 |
| 3M Ago | 2 | 0 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $48.11, with a high estimate of $60.00 and a low estimate of $38.00. Surpassing the previous average price target of $44.63, the current average has increased by 7.8%.
Breaking Down Analyst Ratings: A Detailed Examination
The analysis of recent analyst actions sheds light on the perception of Exelixis by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Robert Burns | HC Wainwright & Co. | Lowers | Buy | $46.00 | $53.00 |
| Ashwani Verma | UBS | Lowers | Neutral | $38.00 | $43.00 |
| Asthika Goonewardene | Truist Securities | Lowers | Buy | $49.00 | $56.00 |
| Sean Laaman | Morgan Stanley | Lowers | Overweight | $46.00 | $48.00 |
| Leonid Timashev | RBC Capital | Lowers | Sector Perform | $45.00 | $50.00 |
| Silvan Tuerkcan | JMP Securities | Maintains | Market Outperform | $50.00 | $50.00 |
| Michael Schmitz | Guggenheim | Maintains | Buy | $45.00 | $45.00 |
| Stephen Willey | Stifel | Raises | Hold | $41.00 | $38.00 |
| Jefferson Harralson | Morgan Stanley | Raises | Overweight | $48.00 | $47.00 |
| Asthika Goonewardene | Truist Securities | Raises | Buy | $56.00 | $55.00 |
| Ashwani Verma | UBS | Raises | Neutral | $43.00 | $38.00 |
| Peter Lawson | Barclays | Raises | Equal-Weight | $40.00 | $29.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Buy | $53.00 | $47.00 |
| Sudan Loganathan | Stephens & Co. | Raises | Overweight | $60.00 | $29.00 |
| Asthika Goonewardene | Truist Securities | Raises | Buy | $55.00 | $43.00 |
| Silvan Tuerkcan | JMP Securities | Raises | Market Outperform | $50.00 | $47.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Buy | $47.00 | $40.00 |
| Jason Gerberry | B of A Securities | Raises | Neutral | $46.00 | $45.00 |
| David Lebowitz | Citigroup | Raises | Buy | $56.00 | $45.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Exelixis's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Exelixis's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Exelixis analyst ratings.
Get to Know Exelixis Better
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Exelixis: Financial Performance Dissected
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Exelixis's revenue growth over 3M faced difficulties. As of 30 June, 2025, the company experienced a decline of approximately -10.82%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exelixis's net margin is impressive, surpassing industry averages. With a net margin of 32.53%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Exelixis's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 8.88%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Exelixis's ROA stands out, surpassing industry averages. With an impressive ROA of 6.7%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Exelixis adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: What Are They?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
